No substantial link between swine flu vaccine and Guillain-Barre syndrome, confirm experts

Adjuvanted vaccines used during the 2009 swine flu pandemic did not increase the risk of Guillain-Barré syndrome substantially, if at all, finds a large Europe-wide study published in the British Medical Journal today. An adjuvant is a substance added to a vaccine to stimulate the immune system to respond to the vaccine.

The study provides reassurance about potential risks of adjuvanted vaccines. It also exemplifies the use of a newly available infrastructure in Europe, which may help to provide reliable risk assessments related to future concerns.

Guillain-Barré is a rare disorder in which a person's own immune system damages the nerve cells, causing muscle weakness and sometimes paralysis.

In 1976, a used during a US was linked with the syndrome and vaccination was stopped abruptly. Since then, studies have shown no or only slight increases in risk but, to date, the role of flu vaccines as a trigger in Guillain-Barré syndrome remains controversial.

Therefore, the European Centre for Disease Prevention and Control (ECDC) requested and funded a consortium of European researchers (VAESCO) to estimate the risk of Guillain-Barré syndrome following pandemic influenza A (H1N1) 2009 vaccination.

The study published in BMJ today was carried out in a population of 50 million people across five European countries which vaccinated people during the 2009 . A total of 104 cases of Guillain-Barré syndrome (and its variant Miller Fisher syndrome) were matched to one or more controls.

After adjusting for recognised risk factors, such as influenza-like illness or upper respiratory tract infection, and seasonal influenza vaccination, the researchers could find no association between pandemic flu vaccination and Guillain-Barré syndrome. The consistent pattern across countries also provides reassurance about the findings, they add.

However, they point out that they cannot rule out the possibility of a small increased risk remaining.

Based on these results, they estimate this risk to be less than three excess cases of Guillain-Barré syndrome for every million individuals protected by the vaccination.

They conclude: "This study provides reassurance that adjuvanted pandemic influenza A (H1N1) 2009 vaccines did not increase the risk of Guillain-Barré syndrome substantially, if at all." They also say that larger studies, using different techniques to minimise bias, are currently underway that will give a clearer picture of the link between flu vaccines and Guillain-Barré syndrome.

This view is supported in an accompanying editorial by US researchers, who say the risk of Guillain-Barré syndrome, if any, is considerably smaller than that seen with the 1976 vaccines. They add that safety findings on adjuvanted flu vaccines are important if such vaccines become more common in future, whether in seasonal vaccines or for the next pandemic.


Explore further

Large study reaffirms H1N1, seasonal flu vaccine safety

Citation: No substantial link between swine flu vaccine and Guillain-Barre syndrome, confirm experts (2011, July 13) retrieved 23 October 2021 from https://medicalxpress.com/news/2011-07-substantial-link-swine-flu-vaccine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors